Has the potential for genotoxicity and carcinogenicity.
- INDICATIONS: Chagas disease (trypanosomiasis) in pediatric patients aged 2–12 years
- CLASS: Antibiotic, Antibiotic; nitroimidazole, Antimicrobial
- HALF-LIFE: 13 hours
- FDA APPROVAL DATE: 08/29/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Disulfiram - PREGNANCY: Can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 01/19/2024
